Select region
Menu
  • Products and Solutionsmore
    • Intensive Care
    • Cardiovascular Procedures
    • Operating Room
    • Sterile Reprocessing
    • Digital Health
    • Pharmaceutical Production
    • Research Laboratories

    • View all products →
  • Servicesmore
    • Technical Services
    • Digital Services
    • Financial Services
    • Planning and Design
    • Project Implementation
    • Education and Training
    • Hospital Transformational Partnerships

    • View all Services →
  • Insightsmore
    • Academy
    • Articles
    • Events
    • Getinge Experience Center
    • Idea and invention submission

    • Insights main page →
  • Companymore
    • Corporate Governance
    • Sustainability
    • Business Ethics
    • News
    • Careers
    • Investors
    • Grants and Charitable Donations
    • History

    • Company main page →
  • Loginmore
    • Instruction For Use and Patient Info
    • Getinge FleetView
    • ServiceNow
    • Distributor Portal
    • Hospital Planning Platform

    • Login page →
    • News
    • Legal Information
    • Instructions For Use/Patient Information
    • Product Catalog
    • Investors
    • Careers
  • Contact
  • International (English)
    • Global
      • International (English)
    • EMEA
      • Sverige (Svenska)
      • Deutschland (Deutsch)
      • France (Français)
      • United Kingdom / Ireland (English)
      • Italia (Italiano)
      • Türkiye (Türkçe)
      • Polska (polski)
      • Россия (русский)
      • Spain (Español)
      • Denmark (Dansk)
      • Norge (Norsk)
      • Suomi (Suomalainen)
      • Benelux (Nederlands)
    • Americas
      • United States (English)
      • Brazil (Português)
      • Canada (English)
      • Canada (Français)
      • Latin America (Español)
    • Asia
      • 日本 (日本語)
      • 中国 (中文)
      • 한국어(대한민국)
      • South East Asia (English)
      • India (English)
    • Oceania
      • Australia / New Zealand (English)
  • Login
    • Instruction For Use and Patient Info
    • Getinge FleetView
    • ServiceNow
    • Distributor Portal
    • Hospital Planning Platform

    • Login page →
  • Products and Solutions
    • Intensive Care
    • Cardiovascular Procedures
    • Operating Room
    • Sterile Reprocessing
    • Digital Health
    • Pharmaceutical Production
    • Research Laboratories

    • View all products →
  • Services
    • Technical Services
    • Digital Services
    • Financial Services
    • Planning and Design
    • Project Implementation
    • Education and Training
    • Hospital Transformational Partnerships

    • View all Services →
  • Insights
    • Academy
    • Articles
    • Events
    • Getinge Experience Center
    • Idea and invention submission

    • Insights main page →
  • Company
    • Corporate Governance
    • Sustainability
    • Business Ethics
    • News
    • Careers
    • Investors
    • Grants and Charitable Donations
    • History

    • Company main page →
  • Contact
  • Start
  • Insights
  • Articles
  • Intensive Care
  • Sepsis and PiCCO

Hemodynamic Management in Sepsis Patients

Topic
Intensive Care
Sepsis treatment
Topic
Intensive Care

Reduce the burden of a global health crisis

Everyone is at risk of developing sepsis. Globally, up to 50 million people are affected by sepsis, every year. Every 2.8 seconds, one patient dies from sepsis and associated complications. Often, it can be prevented by vaccination, clean water and hygiene, safe childbirth, and preventing hospital-acquired infections (HAIs). However, sepsis is often underdiagnosed, especially at an early stage where treatments are more successful. [1]

Sepsis is a medical emergency with high mortality rates. Sepsis survivors often suffer long-term disabilities. One out of four sepsis patients does not survive hospitalization. [2], [3]

Sepsis is defined as a dysregulated immune response to an infection that injures the body's tissues and organs. As a life-threatening organ dysfunction, sepsis can lead to shock and multi-organ failure. If not recognized early and treated promptly, sepsis often leads to death. Sepsis is the most common way to die from an infectious disease worldwide, including viruses such as SARS-CoV-2. Hospital-acquired sepsis accounts for more than 40% of mortality rates and is still one of the most common complications in Intensive Care Units. [4], [5], [6]

icons_Septic_RGB_144_01_ICUpatients_Berry120.jpg icons_Septic_RGB_144_02_Mortality_Berry120.jpg icons_Septic_RGB_144_03_AverageCosts_Berry120.jpg

60 - 80% of ICU Patients with sepsis were infected inside the hospital [7]

100% higher probability to die in the next 5 years [8]

76.000€ average cost per septic patient in Germany [9]

What causes sepsis?

  • The infection is most commonly caused by infections by bacteria, fungi, viruses, or parasites. 
  • The primary sources of infections resulting in sepsis are the lungs, abdomen, urinary tract, or skin.
  • 50 % of all sepsis cases start as an infection in the lungs.
  • No definitive source is found in 35 % to 50 % of cases.
  • Endotoxins initiate a pathophysiological cascade.
  • Dysregulation of the proinflammatory response of cytokines, which promotes tissue-damaging inflammation.

Sepsis symptoms

Symptoms of Sepsis

Sepsis and SARS-CoV-2

"...COVID-19 does indeed cause sepsis."

Today, it's known that COVID-19 can cause severe pneumonia, other organs can be affected by SARS-CoV-2, too. Multi-organ injury, which is typical for sepsis, occurs in 2-5 % of COVID-19 patients, after approximately 8-10 days. Sepsis and its complications are reasons for high mortality amongst COVID-19 patients. Therefore, knowing and recognizing early signs of sepsis is crucial for the initiation of treatment. Timely intervention after diagnosis can save lives and prevent harm to vital organ functions. [10]

Hemodynamic sepsis management

Hemodynamic management is a key therapeutic aspect in treating patients with sepsis or septic shock. [10] 

The hemodynamic management of patients with sepsis and septic shock is an important cornerstone for treatment and resuscitation. Delayed or inadequate hemodynamic management can have serious outcomes. Hypoperfusion, tissue hypoxia, edema, and fluid overload, may lead to multiple organ failures. [11] 

Hemodynamic stabilization is crucial after a sepsis diagnosis. Deliver immediate fluid resuscitation while obtaining other important laboratory results like lactate levels, blood cultures, and antibiotics is of great importance. [12], [13]. Also,  hemodynamic monitoring can help identify the type of sepsis and supports drug management.

The goal of advanced monitoring and managing hemodynamic parameters in sepsis patients is to optimize and restore the balance between oxygen demand and supply at the tissue level. A goal-oriented therapy approach should be followed, ensuring adequate perfusion and the balance of oxygen levels, with a continuous mean arterial pressure above 65 mmHg. [11]

How to use PiCCO for sepsis therapy

PiCCO provides and monitors a number of important parameters including continuous cardiac output at the bedside which can have an impact on clinical decisions. These parameters help identify adequate fluid resuscitation, without the risk of fluid overload. PiCCO monitoring also optimizes the administration of catecholamines and vasoactive agents.

Hemodynamic sepsis management within first 24 hours

Hemodynamic sepsis management within first 24 hours

[11], Values measured in: CI = L/min/m2 · GEDI = mL/m2 · ELWI = mL/kg · MAP = mmHg

Hemodynamic sepsis management after first 24 hours

Hemodynamic sepsis manangement after first 24 hours

[11], Values measured in: CI = L/min/m2 · GEDI = mL/m2 · ELWI = mL/kg · MAP = mmHg

Related Articles

View all

ECMO helps save lives in regional hospitals

When a 68-year old Finnish man’s heart stopped beating, the close proximity to the only regional, non-university hospital in the Nordic region with Extracorporeal Membrane Oxygenation (ECMO) service helped to save him.

Intensive Care

ECMO and COVID-19

The COVID-19 pandemic has created a unique challenge to test whether extracorporeal membrane oxygenation (ECMO) can increase the survival of critically ill patients with severe acute respiratory distress syndrome (ARDS). Emerging research shows a mortality benefit for COVID-19 patients with ARDS who are supported with ECMO. But which types of patients benefit most, and under which conditions?

Intensive Care

Esophageal and Transpulmonary pressure monitoring

Dutch intensive care physician and researcher Heder de Vries, shares his insights into the implementation of Transpulmonary pressure monitoring.

Intensive Care

All references

  1. 1. https://www.global-sepsis-alliance.org/sepsis

  2. 2. Iwashyna TJ., Cooke CR., Wunsch H., Kahn JM., Population burden of long-term survivorship after severe sepsis in older Americans. J Am Geriatr Soc (2012) 60:1070–1077

  3. 3. Fleischmann-Struzek C., Mellhammar L., Rose N., et al. Incidence and mortality of hospital- and ICU-treated sepsis: results from an updated and expanded systematic review and meta-analysis. Intensive Care Med 46, 1552–1562 (2020). https://doi.org/10.1007/s00134-020-06151-x

  4. 4. https://www.worldsepsisday.org/sepsisfacts

  5. 5. https://www.who.int/news-room/fact-sheets/detail/sepsis

  6. 6. Markwart R., Saito H., Harder T. et al. Epidemiology and burden of sepsis acquired in hospitals and intensive care units: a systematic review and meta-analysis. Intensive Care Med 46, 1536–1551 (2020). https://doi.org/10.1007/s00134-020-06106-2

  7. 7. Kissoon N., Carcillo JA., Espinosa V.,et. al. World Federation of Pediatric Intensive Care and Critical Care Societies: Global Sepsis Initiative. Pediatr Crit Care Med, 2011. 12(5): p. 494-503.

  8. 8. Angus DC. The lingering consequences of sepsis: a hidden public health disaster? JAMA,
    2010. 304(16):1833-4.

  9. 9. Moerer, O., Burchardi, H. Kosten der Sepsis. Anaesthesist 55;2006, 36–42 https://doi.org/10.1007/s00101-006-1039-y

  10. 10. https://www.global-sepsis-alliance.org/news/2020/4/7/update-can-covid-19-cause-sepsis-explaining-the-relationship-between-the-coronavirus-disease-and-sepsis-cvd-novel-coronavirus

  11. 11. Saugel B., Huber W., Nierhaus A., Kluge S., Reuter D., Wagner J., Advanced Hemodynamic Management in Patients with Septic Shock", BioMed Research International, vol. 2016, Article ID 8268569, 11 pages, 2016. https://doi.org/10.1155/2016/8268569

  12. 12. Virág, M.; Leiner, T.; Rottler, M.; Ocskay, K.; Molnar, Z.Individualized Hemodynamic Management in Sepsis. J. Pers. Med. 2021, 11, 157. https://doi.org/10.3390/jpm11020157

  13. 13. Levy, M.M., Evans, L.E. & Rhodes, A. The Surviving Sepsis Campaign Bundle: 2018 update. Intensive Care Med 44, 925–928 (2018). https://doi.org/10.1007/s00134-018-5085-0

You are now leaving Getinge.com. You might access content  not managed by Getinge team, in that case Getinge can not be hold responsible of the content. 

I understand!

Our offer

  • Products and Solutions
  • Services

Support and tools

  • Insights
  • Events
  • Past Webinars
  • Instructions For Use/Patient Information
  • Security

Company

  • Investors
  • Careers
  • Corporate Governance
  • History
  • Legal Information
  • Getinge Privacy Center
  • Website use disclaimer
Get in contact
International (English)
  • Global
    • International (English)
  • EMEA
    • Sverige (Svenska)
    • Deutschland (Deutsch)
    • France (Français)
    • United Kingdom / Ireland (English)
    • Italia (Italiano)
    • Türkiye (Türkçe)
    • Polska (polski)
    • Россия (русский)
    • Spain (Español)
    • Denmark (Dansk)
    • Norge (Norsk)
    • Suomi (Suomalainen)
    • Benelux (Nederlands)
  • Americas
    • United States (English)
    • Brazil (Português)
    • Canada (English)
    • Canada (Français)
    • Latin America (Español)
  • Asia
    • 日本 (日本語)
    • 中国 (中文)
    • 한국어(대한민국)
    • South East Asia (English)
    • India (English)
  • Oceania
    • Australia / New Zealand (English)
International (English)

© 2025 Getinge │ Getinge and

Getinge_Logo_hz_RGB_neg.png

are trademarks or registered trademarks of Getinge AB, its subsidiaries or affiliates │All rights reserved.

January 2025

This information is aimed exclusively at healthcare professionals or other professional audiences and is for informational purposes only, is not exhaustive and therefore should not be relied upon as a replacement of the Instructions for Use, service manual or medical advice. Getinge shall bear no responsibility or liability for any action or omission of any party based upon this material, and reliance is solely at the user’s risk.

Any therapy, solution or product mentioned might not be available or allowed in your country. Information may not be copied or used, in whole or in part, without written permission by Getinge.

This information is intended for an international audience outside the US.

Views, opinions, and assertions expressed are strictly those of the interviewed and do not necessarily reflect or represent the views of Getinge.